Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.24.2.u1
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended 16 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Jun. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty income $ 726,404 $ 651,005 $ 1,237,221 $ 1,256,849    
Research and development expenses 933,771 903,243 1,878,092 1,498,519    
Prepaid expenses and other current assets 716,381   716,381   $ 603,828 $ 716,381
Revenues 726,404 651,005 1,237,221 1,256,849    
Collaborative Agreements [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenues 0 $ 0 0 $ 0    
Catalent Pharma Solutions [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses     2,500,000      
Prepaid expenses and other current assets 28,000   28,000   100,000 28,000
Accrued expenses and other current liabilities 49,000   49,000   0 49,000
Other assets 300,000   300,000   300,000 300,000
Scripps Research [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses           900,000
Prepaid expenses and other current assets $ 100,000   100,000   400,000 $ 100,000
University Of Virginia [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses     $ 200,000   $ 0